Genelux Corporation (GNLX) Investor Relations Documents

Genelux Corporation (GNLX) investor relations documents from the company's IR site: 1 presentation, 36 press releases; latest deck 2026-08-13. Read in-app with summaries. First-party data.

Genelux Corporation Presentation – August 2026: Genelux's Olvi-Vec is a next-gen oncolytic virus for ovarian and lung cancers, with Phase 3 ovarian cancer data expected in 2H 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13PresentationGenelux Corporation Presentation – August 2026
2026-08-13Press releaseGenelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
2026-06-30Press releaseGenelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with
2026-06-06Press releasePDF Version
2026-05-07Press releasePDF Version
2026-05-07Press releaseGenelux Corporation Reports First Quarter Financial Results and Provides Business Updates
2026-03-19Press releasePDF Version
2026-03-19Press releaseGenelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-02-18Press releaseGenelux Corporation to Participate in Upcoming Conferences
2026-01-12Press releaseGenelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
2026-01-08Press releaseGenelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
2026-01-07Press releaseGenelux Corporation Announces Proposed Public Offering of Common Stock
2026-01-05Press releaseGenelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trial
2026-01-02Press releaseGenelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
2025-11-26Press releaseGenelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
2025-09-02Press releasePDF Version
2025-09-02Press releaseGenelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
2025-05-01Press releasePDF Version
2025-05-01Press releaseGenelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
2025-03-28Press releasePDF Version
2025-03-28Press releaseGenelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-03-25Press releasePDF Version
2025-03-25Press releasePDF Version
2025-03-25Press releaseGenelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refracto
2025-03-25Press releaseGenelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
2024-12-13Press releasePDF Version
2024-11-14Press releaseGenelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
2024-11-06Press releasePDF Version
2024-08-14Press releasePDF Version
2024-08-14Press releaseGenelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
2024-05-09Press releaseGenelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
2024-04-01Press releaseGenelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2023-11-14Press releasePDF Version
2023-11-14Press releaseGenelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
2023-08-14Press releasePDF Version
2023-08-14Press releaseGenelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
2020-09-16Press releasePDF Version

GNLX overview · GNLX earnings · GNLX financials · GNLX KPIs · GNLX ownership · GNLX peers · GNLX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.